Occam Places Jorge Bartolome as CEO at Areteia Therapeutics

Areteia Therapeutics, a private clinical stage biotech that just raised $350M in a Series A led by Bain Capital, is the product of a collaboration between Clive Meanwell’s Population Health Partners and Knopp Biosciences. The recent robust financing round will be used to advance its lead candidate, dexpramipexole, a small molecule in phase 3 development, one holding out great promise as the first oral therapy for asthma. If successful, this compound represents a potential game changing treatment for an ubiquitous and difficult to treat chronic condition.

Jorge enters the fray at a critical point in the company’s evolution. He  brings powerful domain expertise and decades of commercial leadership to the party. Previously, Bartolome served as President of Canada for Janssen and, prior to that, as SVP of the US Respiratory Business Unit of GSK.

See Full Press Release HERE

Occam Recruits Michael Miller to the Board of BioXcel

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, has appointed Michael Miller to its Board of Directors. Michael brings multiple decades of strategic leadership and commercial growth experience in the pharmaceutical industry, having most recently served as Executive Vice President, U.S. Commercial at Jazz Pharmaceuticals. Michael led a 450+ person commercial team that generated $2.3 billion in revenues in 2020.

Prior to Jazz, he served in senior executive management positions with commercial, marketing, market access, and sales responsibilities at VIVUS, Genentech (until acquisition by Roche), Connetics Corporation, and ALZA Corporation.

Michael holds a B.S. in Finance from the University of San Francisco and an M.B.A. from San Francisco State University.

See Full Press Release HERE

Occam Places Dan Marquess as CSO at Vicinitas Therapeutics

 

Occam’s commitment to help meaningfully shape and build structure in high science platform companies has yielded another impressive result in the placement of Dan Marquess as CSO at Vicinitas, Dan Nomura’s latest creation that seeks to commercialize a compellingly novel approach to drugging the “undruggable.”

With $65M in the bank from Deerfield and a16z and with Marquess leading the scientific charge, Vicinitas is well positioned to deliver on the platform’s formidable potential around leveraging protein stabilization to develop a novel class of therapeutics.

Prior to Vicinitas, Marquess was the CSO at UNITY Biotechnology and prior to that role had spent more than 15 years at Theravance.

Dan earned his D.Phil in Chemistry from Oxford University and his undergraduate degree in Chemistry from Queens University.

 

Occam Places Paul Thibodeau as CBO of Hotspot

HotSpot Therapeutics, an Atlas investment that has raised $190M to date, is pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases.

Thibodeau joins HotSpot from Novartis where he held numerous business development positions, most recently leading M&A transactions across all of Novartis’ therapeutic areas, where he was responsible for deal sourcing, evaluation, and execution of acquisitions and divestments. Prior to joining Novartis in 2016, he served as Senior Director of Global Business Development at Teva Cephalon, heading up all out-licensing and discovery deals for its specialty pipeline. Previously, he held numerous business development positions with increasing responsibilities at Sanofi Genzyme across its oncology, transplant and multiple sclerosis franchises.

Thibodeau was a Postdoctoral Research Fellow at the Institut national scientifique et de la recherche médicale (INSERM) in Paris, France. He received his Ph.D. in Cell Biology and Radiobiology from the Université de Sherbrooke in Quebec, Canada, and his B.S. in Biology and Biochemistry from the Université de Moncton in New Brunswick, Canada. He also completed a MBA at the MIT Sloan School of Management.

Occam Places Amber Salzman as CEO of Epic Bio

As CEO of Epic, Salzman, who just raised $55M in a series A financing, will work closely with Stanley Qi, Ph.D., a renowned bioengineer and co-inventor on the CRISPR patent held by the University of California, to further develop his vision to use the smallest known Cas protein in epigenetic engineering.

Epic has developed the GEMS platform to precisely modify gene expression. GEMS includes the largest known library of novel modulators combined with advanced functional and computational genomics capabilities to rapidly design guide RNAs that are highly specific to the targeted genes.

The company additionally launches with an exclusive license from Stanford University to the ultracompact DNA-binding protein CasMINI for human use. CasMINI is the smallest Cas protein created to date, developed in the lab of Dr. Qi. It is less than half the size of Cas9 and Cas12a and is engineered to function robustly in mammalian cells. The small size of CasMINI enables delivery of Epic’s therapeutic candidates in vivo via a single AAV vector to a wide range of target organs.

Prior to joining Epic Bio, Amber served as the President and CEO of Ohana Biosciences, pioneering the industry’s first sperm biology platform. Before Ohana, she served as the President and CEO of Adverum Biotechnologies and was co-founder of Annapurna, SAS before its merger with Avalanche Biotechnologies to become Adverum.

Amber received her bachelor’s degree from Temple University and holds a PhD in mathematics from Bryn Mawr College.

Chris Gibson

CEO | Recursion Pharmaceuticals

"Occam has been a formidable recruiting partner for Recursion. Over the past three years, they have helped us make key additions to the senior executive team and Board. The firm has consistently provided a unique blend of nuanced and ethical judgement, tireless and creative effort, and strategic insight in helping us develop a holistic organizational plan as Recursion has evolved."
Find out more Read the Case Study

Julie Sunderland

Managing Director | Biomatics Capital

"Bill Holodnak’s deep understanding of humanity allows him to match people and opportunities in a magical, almost musical way. In other words, it’s jazz baby."
Find out more

Josh Wolfe

Co-Founder & Managing Partner | Lux Capital

"Occam has been a great and valued recruiting partner for Lux. They impress with business moxie, psychological acuity, ruthless objectivity and speed. A team and search firm apart."
Find out more

Bob More

Managing Director | Alta Partners

"Occam brings an uncommon mix of intelligence, discipline and instinct to executive recruiting. Building companies is more art than science; they bring both to the party. In enduring fashion, Occam has mastered the human side of venture capital."
Find out more

Frederic Kerrest

Executive Vice Chairperson, COO & Co-Founder | Okta

“Thorough, tireless, and professional, and they listen. Occam is a search firm that matches the entrepreneurial intensity of its clients. Results delivered with intelligence, urgency and style.”
Find out more

Recent Placements

Occam Places Jorge Bartolome as CEO at Areteia Therapeutics

Find out more

Occam Recruits Michael Miller to the Board of BioXcel

Find out more

Occam Places Dan Marquess as CSO at Vicinitas Therapeutics

 

Find out more

Occam Places Paul Thibodeau as CBO of Hotspot

Find out more

Occam Places Amber Salzman as CEO of Epic Bio

Find out more

Why Occam?

Occam Global is a strategic human capital advisory firm dedicated to rigorous objectivity and enlightened aggression in executive recruiting and organizational development.

Our mission is to work selectively with exceptional clients for the long term. If candor and completeness is your preference in matters of Human Capital, the most opaque of asset classes, Occam is the partner for you.

The medieval philosopher William of Occam is the firm’s adopted patron saint. William spoke plainly and thought with rigor and humanity. These qualities yielded elevated ideas and also got him into a few punch-ups with the Holy See. His enduring concept, Occam’s Razor—“Lex Parsimoniae”—embodies an unrelenting focus on essentials in problem solving. His and our solutions strive for elegant simplicity.

  • Rich expertise and global contacts in technology, healthcare, financial services, and entrepreneurial organizations
  • Objective yet unconventional approach to problem solving
  • Virtually no off-limits constraints
  • Milestone-driven fee structure
Meet our executive headhunters

Services

Occam’s commitment is to provide an abundance of precisely qualified candidates through an open inquiry; due diligence for selection; and guidance on closure and integration. Our approach is relationship rather than transaction-driven.

Executive Search

Find out more
+
Executive
Placements
+
Board
Placements

Board of Directors Search

Find out more

Human Venture Capital

Find out more

Industries

Occam works with a wide range of high-growth industries as a trusted partner in executive recruitment.

  • Biotechnology
  • Pharmaceuticals
  • Life Sciences
  • Medical Devices
  • Healthcare
  • Technology
  • FinTech
  • Sustainable Energy
  • Venture Capital
  • Private Equity

Select Clients

  • Recursion Pharamceuticals
  • Elicio Therapeutics
  • PACT Pharma
  • Pacira Biosciences Inc.
  • Tmunity
  • CytomX Therapeutics
  • Generation Bio
  • Beam Therapeutics
  • Variant Bio
  • Semma Therapeutics
  • eGenesis Engineering
  • Oncorus
Previous Slide Next Slide

News & Views

Industry insights, client successes, and a deeper dive into the world of executive search and C-suite recruiting.

View all news

Occam Places Jorge Bartolome as CEO at Areteia Therapeutics

Read Story

Occam Recruits Michael Miller to the Board of BioXcel

Read Story

Occam Places Dan Marquess as CSO at Vicinitas Therapeutics

Read Story

Occam Places Paul Thibodeau as CBO of Hotspot

Read Story

Occam Places Amber Salzman as CEO of Epic Bio

Read Story

Occam Places Colin McCracken as Chief Executive Officer at Evonetix

Read Story

Contact

145 Hudson Street, Suite 5B
New York, NY, 10004
United States

    I am interested in*